AstraZeneca EMERALD-3 Phase III Trial Shows IMFINZI Plus IMJUDO With Lenvatinib And TACE Improves PFS In Embolization-Eligible Liver Cancer

AstraZeneca's EMERALD-3 Phase III trial results indicate that the combination of IMFINZI plus IMJUDO with lenvatinib and transarterial chemoembolization (TACE) significantly improves progression-free survival in patients with embolization-eligible unresectable liver cancer. The trial also showed a trend toward improved overall survival. This development may impact AstraZeneca's market position in oncology treatments.